To better understand the basis for therapeutic resistance and poor clinical outcomes in PEL, we examined the activation status of key oncogenic and survival signaling pathways, including mTORC1, AKT, PI3K, FOXO, and NF‐κB. The gene discussed is NFKB1; the disease is primary effusion lymphoma.